Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis
- PMID: 22358431
- DOI: 10.1007/s00259-012-2087-y
Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis
Abstract
Purpose: The aim of this study was to systematically review and conduct a meta-analysis of published data about the diagnostic performance of (18)F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) in patients with paraganglioma (PG).
Methods: A comprehensive computer literature search of studies published through 30 June 2011 regarding (18)F-DOPA PET or PET/computed tomography (PET/CT) in patients with PG was performed in PubMed/MEDLINE, Embase and Scopus databases. Pooled sensitivity and specificity of (18)F-DOPA PET or PET/CT in patients with PG on a per patient- and on a per lesion-based analysis were calculated. The area under the receiver-operating characteristic (ROC) curve was calculated to measure the accuracy of (18)F-DOPA PET or PET/CT in patients with PG. Furthermore, a sub-analysis taking into account the different genetic mutations in PG patients was also performed.
Results: Eleven studies comprising 275 patients with suspected PG were included in this meta-analysis. The pooled sensitivity of (18)F-DOPA PET and PET/CT in detecting PG was 91% [95% confidence interval (CI) 87-94%] on a per patient-based analysis and 79% (95% CI 76-81%) on a per lesion-based analysis. The pooled specificity of (18)F-DOPA PET and PET/CT in detecting PG was 95% (95% CI 86-99%) on a per patient-based analysis and 95% (95% CI 84-99%) on a per lesion-based analysis. The area under the ROC curve was 0.95 on a per patient- and 0.94 on a per lesion-based analysis. Heterogeneity between the studies about sensitivity of (18)F-DOPA PET or PET/CT was found. A significant increase in sensitivity of (18)F-DOPA PET or PET/CT was observed when a sub-analysis excluding patients with succinate dehydrogenase subunit B (SDHB) gene mutations was performed.
Conclusion: In patients with suspected PG (18)F-DOPA PET or PET/CT demonstrated high sensitivity and specificity. (18)F-DOPA PET or PET/CT are accurate methods in this setting. Nevertheless, possible sources of false-negative results should be kept in mind. Furthermore, SDHB gene mutations could influence (18)F-DOPA PET or PET/CT diagnostic performance.
Similar articles
-
Diagnostic performance of FDG PET or PET/CT in prosthetic infection after arthroplasty: a meta-analysis.Q J Nucl Med Mol Imaging. 2014 Mar;58(1):85-93. Q J Nucl Med Mol Imaging. 2014. PMID: 24469570
-
Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis.Acad Radiol. 2014 Jan;21(1):11-20. doi: 10.1016/j.acra.2013.09.015. Acad Radiol. 2014. PMID: 24331260 Review.
-
Diagnostic role of 18F-dihydroxyphenylalanine positron emission tomography in patients with congenital hyperinsulinism: a meta-analysis.Nucl Med Commun. 2013 Apr;34(4):347-53. doi: 10.1097/MNM.0b013e32835e6ac6. Nucl Med Commun. 2013. PMID: 23376859
-
Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis.Pediatr Radiol. 2012 Nov;42(11):1372-9. doi: 10.1007/s00247-012-2459-2. Epub 2012 Aug 12. Pediatr Radiol. 2012. PMID: 22885604 Review.
-
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.J Clin Endocrinol Metab. 2009 Dec;94(12):4757-67. doi: 10.1210/jc.2009-1248. Epub 2009 Oct 28. J Clin Endocrinol Metab. 2009. PMID: 19864450 Free PMC article.
Cited by
-
Pitfalls in the Diagnostic Evaluation of Pheochromocytomas.J Endocr Soc. 2024 May 8;8(6):bvae078. doi: 10.1210/jendso/bvae078. eCollection 2024 Apr 6. J Endocr Soc. 2024. PMID: 38737592 Free PMC article.
-
Application of Metabolic Reprogramming to Cancer Imaging and Diagnosis.Int J Mol Sci. 2022 Dec 13;23(24):15831. doi: 10.3390/ijms232415831. Int J Mol Sci. 2022. PMID: 36555470 Free PMC article. Review.
-
[18F]mFBG PET/CT imaging outperforms MRI and [68 Ga]Ga-DOTA-TOC PET/CT in identifying recurrence pheochromocytoma.Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1538-1540. doi: 10.1007/s00259-022-06064-5. Epub 2022 Dec 15. Eur J Nucl Med Mol Imaging. 2023. PMID: 36517705 No abstract available.
-
Imaging pheochromocytoma in small animals: preclinical models to improve diagnosis and treatment.EJNMMI Res. 2021 Dec 11;11(1):121. doi: 10.1186/s13550-021-00855-x. EJNMMI Res. 2021. PMID: 34894301 Free PMC article. Review.
-
PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses.Cancers (Basel). 2021 Oct 15;13(20):5172. doi: 10.3390/cancers13205172. Cancers (Basel). 2021. PMID: 34680321 Free PMC article. Review.